For most HIV patients today, treatment is a single pill taken once a day. It's a medical miracle that many of us take for granted — the result of decades of research that transformed a death sentence into a manageable chronic condition.
But not for everyone.
Estimated at tens of thousands of patients in the US alone, and many more globally, there is a 'forgotten population' of people living with HIV who cannot benefit from modern single-pill treatment. They were diagnosed in the early days of the AIDS epidemic — when the drugs were cruder, the knowledge was limited, and treatments often didn't work well enough to fully suppress the virus. Over years of imperfect treatment, these patients developed resistance to many of the most effective modern HIV medications.
For them, treatment means something very different. It can mean 10 or more drugs, taken at different times throughout the day. It means complex medication schedules, serious side effects, and drugs that interact badly with other medications they need for conditions that come with age.
'Science has moved on for everyone except for them,' said Dr Chloe Orkin, a physician and researcher at Queen Mary University of London who has treated many of these patients. 'They keep asking: why can't I have a single pill? And you have to keep saying no.'
Soon, the answer may be yes.
A new clinical study published in The Lancet and covered by NPR this week has shown that a new once-daily single pill — developed by Gilead Sciences and combining two of their existing drugs into one tablet smaller than a multivitamin — works just as well as the complex multi-drug regimens these patients currently take.
The research was conducted across more than 90 independent trial sites, supported by Gilead but independently run. For the drug-resistant patients in the trial, the results were clear.
'They keep asking, why can't I have a single pill? Can I have injections?' Dr Orkin told NPR. 'Now we can finally say yes.'
This matters not just medically, but humanly. Living with a 10-pill daily regimen is exhausting. It's a daily reminder of illness. It's incompatible with normal life in a way that a once-daily pill is not.
For the patients who survived the worst years of the AIDS epidemic — who took whatever drugs were available, built resistance, and watched everyone else's treatment simplify while theirs stayed complicated — this is the news they've been waiting for.
Science hasn't forgotten them after all. 💊